Skip to main content
Premium Trial:

Request an Annual Quote

Lonza to Sell AllCells Hematopoietic Primary Cell Products

NEW YORK (GenomeWeb) — Swiss biopharmaceutical firm Lonza has signed a private label agreement under which it will offer AllCells' complete portfolio of hematopoietic primary cells under its own branding.

Additional terms of the deal were not disclosed.

"With this partnership, we aim to enable straightforward access to a wealth of viable, ready-to-use hematopoietic cells such as mobilized peripheral blood progenitor cells," Mary Riley, director of discovery solutions at Lonza, said in a statement. "All researchers will need to do is thaw and culture, while also being able to take advantage of Lonza's strong after-sales technical support."

Applications include drug discovery, toxicity testing, cell therapy, and personalized medicine, Lonza said.

In late 2018, Lonza acquired the rights to CRISPR-Cas9 genome editing technology from ERS Genomics. And in mid-2017, it acquired exosome research firm HansaBioMed Life Sciences, as well as invested in cancer test developer Exosomics, as part of a growing interest in cell-derived vesicles as biomarkers.